Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE RANKIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1922027853
CMS profile
132925
Location
DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$406.88

25 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $386.88 24
Gift $20.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE RANKIN

NPI 1922027853 · CMS profile ID 132925

Allopathic & Osteopathic Physicians / Family Medicine

DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922027853?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922027853?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922027853?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1922027853?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

25 matching records · $406.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 25 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–25 of 25.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $27.4408/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774067 CMS
Astellas Pharma US Inc $15.0007/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821507199 CMS
Kowa Pharmaceuticals America, Inc. $12.0607/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805560179 CMS
SANOFI-AVENTIS U.S. LLC $17.4807/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843460929 CMS
AbbVie Inc. $20.4707/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774063 CMS
AbbVie Inc. $15.9907/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774059 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.5507/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763685814 CMS
Teva Pharmaceuticals USA, Inc. $18.3807/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839673591 CMS
IBSA Pharma Inc. $13.1306/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792515161 CMS
PFIZER INC. $20.0006/03/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833592637 CMS
Teva Pharmaceuticals USA, Inc. $14.1506/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839673587 CMS
Kowa Pharmaceuticals America, Inc. $15.3705/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805560173 CMS
AbbVie Inc. $11.6005/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774055 CMS
AbbVie Inc. $15.1905/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774051 CMS
Lilly USA, LLC $11.1504/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818994469 CMS
AbbVie Inc. $10.6104/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774047 CMS
AbbVie Inc. $13.9004/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774043 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.3803/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763685816 CMS
PFIZER INC. $16.8603/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833462559 CMS
AbbVie Inc. $18.2003/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774039 CMS
Novo Nordisk Inc $15.4402/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810881476 CMS
Novo Nordisk Inc $24.2602/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810921759 CMS
Lilly USA, LLC $15.6202/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818988343 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.2201/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820174343 CMS
Lilly USA, LLC $12.4301/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818899861 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,373.98 97
PY2020 $739.07 44
PY2021 $406.88 25
PY2022 $30.36 2
PY2023 $3,057.34 11
PY2024 $1,612.22 12
PY2025 $249.99 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,755.45 1
PY2025 Principal investigator $4,230,288.19 209
PY2024 Recipient $1,330.16 13
PY2024 Principal investigator $3,187,354.20 327
PY2023 Recipient $893.27 4
PY2023 Principal investigator $6,323,793.75 2,767
PY2022 Recipient $462.00 2
PY2022 Principal investigator $6,941,300.42 589
PY2021 Recipient $15.00 1
PY2021 Principal investigator $10,036,876.19 348
PY2020 Recipient $10,602.17 4
PY2020 Principal investigator $3,545,507.10 644
PY2019 Principal investigator $2,410,610.06 875

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

2,771 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $398.57 12/31/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 991132829
Principal investigator 1 Merck Sharp & Dohme LLC $14,566.32 12/31/2023 Non-covered Recipient Entity
Accel Research Sites-DeLand Clinical Research Unit
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 1042488571
Principal investigator 1 Merck Sharp & Dohme LLC $234.24 12/31/2023 Non-covered Recipient Entity
Accel Research Sites-DeLand Clinical Research Unit
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 1042488573
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041444901
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041444914
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041444925
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041444937
Principal investigator 1 ModernaTX, Inc. $2,336.60 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041444947
Principal investigator 1 ModernaTX, Inc. $1,421.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041444959
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445175
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445187
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445201
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445213
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445227
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445239
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445251
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445265
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445279
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445293
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445303
Principal investigator 1 ModernaTX, Inc. $2,336.60 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445313
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445323
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445338
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445351
Principal investigator 1 ModernaTX, Inc. $2,336.60 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445365
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445375
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445385
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445399
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445411
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445425
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445437
Principal investigator 1 ModernaTX, Inc. $2,336.60 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445453
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445467
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445483
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445499
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445513
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445527
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445545
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445559
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445575
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445591
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445607
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445623
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445639
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445653
Principal investigator 1 ModernaTX, Inc. $1,421.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445671
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445685
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445703
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445719
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445735
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445753
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445817
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445831
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445847
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445861
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445877
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445893
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445907
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445923
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445937
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445953
Principal investigator 1 ModernaTX, Inc. $1,421.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445969
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445997
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446335
Principal investigator 1 ModernaTX, Inc. $1,421.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446351
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446367
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446383
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446399
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446415
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446431
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446449
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446465
Principal investigator 1 ModernaTX, Inc. $1,421.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446481
Principal investigator 1 ModernaTX, Inc. $1,421.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446497
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446513
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446527
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446541
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446557
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446573
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446591
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446605
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446619
Principal investigator 1 ModernaTX, Inc. $2,336.60 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446639
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446657
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446671
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446683
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446701
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446719
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446735
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446751
Principal investigator 1 ModernaTX, Inc. $2,336.60 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446765
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446779
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446795
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446809
Principal investigator 1 ModernaTX, Inc. $1,421.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446825
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446841
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446859
Principal investigator 1 ModernaTX, Inc. $1,421.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446877
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446893
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446909
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446925
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446939
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446953
Principal investigator 1 ModernaTX, Inc. $1,421.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446969
Principal investigator 1 ModernaTX, Inc. $2,336.60 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446987
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447003
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447019
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447033
Principal investigator 1 ModernaTX, Inc. $2,336.60 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447049
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447063
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447080
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447095
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447111
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447127
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447145
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447161
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447175
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447189
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447205
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447221
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447235
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447251
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447267
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447283
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447299
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447315
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447331
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447349
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447365
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447381
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447399
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447415
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447429
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447445
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447461
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447477
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447491
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447508
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447521
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447538
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447559
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447573
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447589
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447605
Principal investigator 1 ModernaTX, Inc. $2,336.60 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447621
Principal investigator 1 ModernaTX, Inc. $2,336.60 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447635
Principal investigator 1 ModernaTX, Inc. $1,421.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447651
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447667
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447683
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447699
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447713
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447728
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447743
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447759
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447775
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447793
Principal investigator 1 ModernaTX, Inc. $1,421.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447811
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447825
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447841
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447857
Principal investigator 1 ModernaTX, Inc. $2,336.60 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447871
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447885
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041447903
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041448963
Principal investigator 1 ModernaTX, Inc. $2,510.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041448979
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041448995
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041449011
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041449027
Principal investigator 1 ModernaTX, Inc. $2,336.60 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041449043
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041449060
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041449077
Principal investigator 1 ModernaTX, Inc. $1,421.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041449093
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041449109
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041449123
Principal investigator 1 ModernaTX, Inc. $1,334.20 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041449137
Principal investigator 1 ModernaTX, Inc. $1,652.00 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041449151
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041449167
Principal investigator 1 ModernaTX, Inc. $3,431.40 12/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041449181
Principal investigator 1 Novavax Inc $70,286.12 12/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055263993
Principal investigator 1 ModernaTX, Inc. $750.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041444971
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444985
Principal investigator 1 ModernaTX, Inc. $1,500.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041444999
Principal investigator 1 ModernaTX, Inc. $50.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041445039
Principal investigator 1 ModernaTX, Inc. $650.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041445051
Principal investigator 1 ModernaTX, Inc. $2,563.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445063
Principal investigator 1 ModernaTX, Inc. $1,000.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041445109
Principal investigator 1 ModernaTX, Inc. $310.44 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041445147
Principal investigator 1 ModernaTX, Inc. $66.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041445161
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041445767
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041445783
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041445801
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041445981
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446013
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446029
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446043
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446063
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446075
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446093
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446105
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446121
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446137
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446153
Principal investigator 1 ModernaTX, Inc. $1,000.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041446195
Principal investigator 1 ModernaTX, Inc. $50.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446213
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446275
Principal investigator 1 ModernaTX, Inc. $99.00 12/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446291
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006917863
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006917875
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006917885
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006917895
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006917903
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006917917
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006917927
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006917935
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006917945
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007691351
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007954889
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007954899
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007954909
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007954919
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007954933
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007954943
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007954955
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007954965
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007954975
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007954985
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008580499
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008580515
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008580533
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008580551
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008580567
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008580585
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292591
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292607
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292625
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292641
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292659
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292677
Principal investigator 1 Novo Nordisk AS $18.00 12/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292693
Principal investigator 1 Janssen Research & Development, LLC $1,263.00 12/22/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 986108225
Principal investigator 1 ModernaTX, Inc. $425.00 12/22/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041448899
Principal investigator 1 ModernaTX, Inc. $25.00 12/22/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041448913
Principal investigator 1 ModernaTX, Inc. $25.00 12/22/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041448931
Principal investigator 1 ModernaTX, Inc. $225.00 12/22/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041448947
Principal investigator 1 ModernaTX, Inc. $150,161.62 12/22/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041451037
Principal investigator 1 Janssen Research & Development, LLC $21,284.00 12/20/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108203
Principal investigator 1 Novo Nordisk AS $650.00 12/20/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007691339
Principal investigator 1 Novo Nordisk AS $527.08 12/18/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007691325
Principal investigator 1 IBSA Institut Biochimique SA $2,809.78 12/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH- DELAND, LLC DBA ACCEL RESEARCH SITES
18US-FHp04/A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries No dispute reported 06/30/2026 1005352019
Principal investigator 1 Janssen Research & Development, LLC $500.00 12/15/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108201
Principal investigator 1 Janssen Research & Development, LLC $8,283.00 12/15/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 986108229
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041444063
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444077
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444091
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444173
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444187
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444199
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444213
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444229
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444255
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444267
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444281
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444295
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444309
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444323
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444337
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444351
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444365
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444379
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444393
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444405
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444419
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444433
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444443
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444457
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444471
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444485
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444499
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444513
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444527
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041444541
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444571
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444585
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041444596
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444611
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444625
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444639
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444651
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444677
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444719
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444743
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444759
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444775
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444783
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041444797
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444807
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444819
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444831
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041444845
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444865
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446168
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446179
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446229
Principal investigator 1 ModernaTX, Inc. $1,216.38 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446241
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446259
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446305
Principal investigator 1 ModernaTX, Inc. $539.22 12/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041446319
Principal investigator 1 ModernaTX, Inc. $198.00 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444103
Principal investigator 1 ModernaTX, Inc. $63.36 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444117
Principal investigator 1 ModernaTX, Inc. $1,913.28 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444131
Principal investigator 1 ModernaTX, Inc. $1,797.36 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444145
Principal investigator 1 ModernaTX, Inc. $66.00 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444159
Principal investigator 1 ModernaTX, Inc. $198.00 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444243
Principal investigator 1 ModernaTX, Inc. $198.00 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444553
Principal investigator 1 ModernaTX, Inc. $198.00 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444665
Principal investigator 1 ModernaTX, Inc. $63.36 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444691
Principal investigator 1 ModernaTX, Inc. $63.36 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444705
Principal investigator 1 ModernaTX, Inc. $63.36 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444729
Principal investigator 1 ModernaTX, Inc. $63.36 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444853
Principal investigator 1 ModernaTX, Inc. $63.36 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444879
Principal investigator 1 ModernaTX, Inc. $198.00 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444889
Principal investigator 1 ModernaTX, Inc. $1,200.00 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041451003
Principal investigator 1 ModernaTX, Inc. $1,394.55 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041451071
Principal investigator 1 ModernaTX, Inc. $21,684.51 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041451087
Principal investigator 1 ModernaTX, Inc. $23.00 12/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041452277
Principal investigator 1 Novavax Inc $5,065.00 12/13/2023 Non-covered Recipient Entity
TEXAS CENTER FOR DRUG DEVELOPMENT INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265011
Principal investigator 1 Janssen Research & Development, LLC $276.00 12/07/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108185
Principal investigator 1 Janssen Research & Development, LLC $110.00 12/07/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108187
Principal investigator 1 Janssen Research & Development, LLC $785.00 12/07/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108189
Principal investigator 1 Janssen Research & Development, LLC $589.00 12/07/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108191
Principal investigator 1 Janssen Research & Development, LLC $160.00 12/07/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108193
Principal investigator 1 Janssen Research & Development, LLC $37.00 12/07/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108195
Principal investigator 1 Janssen Research & Development, LLC $110.00 12/07/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108197
Principal investigator 1 Janssen Research & Development, LLC $41.00 12/07/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108199
Principal investigator 1 UCB SA $1,428.04 12/06/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES NETWORK - DELAND CLINICAL RESEARCH UNIT
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1059101691
Principal investigator 1 ModernaTX, Inc. $3,000.00 12/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041448883
Principal investigator 1 Novavax Inc $146,563.15 11/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055261065
Principal investigator 1 Novo Nordisk AS $18.84 11/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007691243
Principal investigator 1 Novo Nordisk AS $18.84 11/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007691255
Principal investigator 1 Novo Nordisk AS $18.84 11/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007691267
Principal investigator 1 Novo Nordisk AS $18.84 11/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007691281
Principal investigator 1 Novo Nordisk AS $18.84 11/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007929931
Principal investigator 1 Janssen Research & Development, LLC $14,127.00 11/28/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108223
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442791
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442805
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442819
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442833
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442847
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442861
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442875
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442887
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442901
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442915
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442929
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442941
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442955
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442983
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442995
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443023
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443037
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443049
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443063
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443075
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443087
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443101
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443115
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443129
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443141
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443155
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443167
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443181
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443195
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443207
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443221
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443235
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443249
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443263
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443275
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443289
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443331
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443345
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443357
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443369
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443383
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443399
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443413
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443427
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443443
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443457
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443469
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443481
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443493
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443507
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443521
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443549
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443561
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443575
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443589
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443603
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443617
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443633
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443645
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443657
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443671
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443685
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443699
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443715
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443729
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443741
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443753
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443767
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443781
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443799
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443811
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443825
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443839
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443855
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443871
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443885
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443895
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443907
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443923
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443937
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443951
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443965
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041443979
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444009
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444023
Principal investigator 1 ModernaTX, Inc. $539.22 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444033
Principal investigator 1 ModernaTX, Inc. $1,216.38 11/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041444047
Principal investigator 1 GlaxoSmithKline, LLC. $3,124.39 11/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1006257457
Principal investigator 1 ModernaTX, Inc. $650.00 11/24/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041450845
Principal investigator 1 Janssen Research & Development, LLC $200.00 11/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140215
Principal investigator 1 ModernaTX, Inc. $3,500.00 11/22/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041443009
Principal investigator 1 ModernaTX, Inc. $500.00 11/22/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041443315
Principal investigator 1 Novo Nordisk AS $2,109.50 11/22/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007691303
Principal investigator 1 Novo Nordisk AS $321.50 11/22/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007691313
Principal investigator 1 Novo Nordisk AS $1,000.00 11/22/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 1008267745
Principal investigator 1 Janssen Research & Development, LLC $78.00 11/20/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 986108233
Principal investigator 1 Janssen Research & Development, LLC $260.00 11/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140211
Principal investigator 1 ModernaTX, Inc. $500.00 11/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041443535
Principal investigator 1 ModernaTX, Inc. $5,000.00 11/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041450969
Principal investigator 1 Janssen Research & Development, LLC $110.00 11/14/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108207
Principal investigator 1 Janssen Research & Development, LLC $462.00 11/14/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108209
Principal investigator 1 Janssen Research & Development, LLC $78.00 11/14/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108211
Principal investigator 1 Janssen Research & Development, LLC $12.00 11/14/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108213
Principal investigator 1 Janssen Research & Development, LLC $2,688.00 11/14/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108215
Principal investigator 1 Janssen Research & Development, LLC $1,923.00 11/14/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108217
Principal investigator 1 Janssen Research & Development, LLC $2,061.00 11/14/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108219
Principal investigator 1 Janssen Research & Development, LLC $110.00 11/14/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108221
Principal investigator 1 ModernaTX, Inc. $1,284.93 11/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442777
Principal investigator 1 ModernaTX, Inc. $1,814.50 11/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442969
Principal investigator 1 Janssen Research & Development, LLC $130.00 11/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140213
Principal investigator 1 Novavax Inc $2,694.60 11/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055263991
Principal investigator 1 GlaxoSmithKline, LLC. $1,631.59 11/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1006257445
Principal investigator 1 Novo Nordisk AS $19.90 11/08/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007929855
Principal investigator 1 Novo Nordisk AS $19.90 11/08/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007929869
Principal investigator 1 Novo Nordisk AS $19.90 11/08/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007929879
Principal investigator 1 Novo Nordisk AS $19.90 11/08/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007929889
Principal investigator 1 Novo Nordisk AS $19.90 11/08/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007929901
Principal investigator 1 Novo Nordisk AS $19.90 11/08/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007929911
Principal investigator 1 Novo Nordisk AS $19.90 11/08/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007929921
Principal investigator 1 Janssen Research & Development, LLC $25.00 11/03/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108205
Principal investigator 1 GlaxoSmithKline, LLC. $22,515.61 11/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1006257489
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 11/01/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108235
Principal investigator 1 ModernaTX, Inc. $20,827.80 11/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041450831
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440853
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440867
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440881
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440895
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440911
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440941
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440969
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440983
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440997
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041441013
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441037
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441045
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041441059
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441069
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441079
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441089
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441103
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441119
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441133
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441163
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441177
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441207
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441223
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441237
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441251
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441265
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441280
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441295
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441309
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441367
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041441383
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041441395
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441423
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441435
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442213
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442227
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041442241
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442254
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442267
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442283
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442297
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442309
Principal investigator 1 ModernaTX, Inc. $155.50 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442323
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442337
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442351
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442363
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442377
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442389
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041442401
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442413
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442425
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442439
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442451
Principal investigator 1 ModernaTX, Inc. $155.50 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442463
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442477
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041442491
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041442505
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041442519
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442533
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442549
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442563
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442577
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442591
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442605
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442619
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442635
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442649
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442663
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442677
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442691
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442703
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442719
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442726
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041442737
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442751
Principal investigator 1 ModernaTX, Inc. $539.22 10/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442765
Principal investigator 1 Bavarian Nordic A/S $500.00 10/25/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695195
Principal investigator 1 Bavarian Nordic A/S $1,500.00 10/25/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695201
Principal investigator 1 Janssen Research & Development, LLC $1,788.00 10/25/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 986108227
Principal investigator 1 Novo Nordisk AS $177.75 10/25/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007691291
Principal investigator 1 ModernaTX, Inc. $67.00 10/24/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041419455
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 10/19/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035896263
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440837
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440923
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440955
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441025
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441147
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441191
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441323
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441337
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441353
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441407
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441449
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441465
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441479
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441491
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441505
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441519
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441533
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441547
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441559
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441645
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441659
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441671
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441755
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441771
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441785
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441883
Principal investigator 1 ModernaTX, Inc. $66.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441919
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441955
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441978
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441991
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442065
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442091
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442105
Principal investigator 1 ModernaTX, Inc. $99.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442159
Principal investigator 1 ModernaTX, Inc. $22,111.07 10/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, Randomized, Observer-blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-based Influenza and SARS-CoV-2 Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1041450877
Principal investigator 1 Bavarian Nordic A/S $682.50 10/11/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695183
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439415
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439429
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439445
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439459
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439472
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439485
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439499
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439513
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439527
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439541
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439555
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439569
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439597
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439615
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439655
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439669
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439711
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439723
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439739
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439755
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439771
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439799
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439811
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439827
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439841
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439869
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439883
Principal investigator 1 ModernaTX, Inc. $155.50 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439925
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439939
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439953
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439967
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439981
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439995
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440011
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440039
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440063
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440077
Principal investigator 1 ModernaTX, Inc. $155.50 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440093
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440109
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440123
Principal investigator 1 ModernaTX, Inc. $155.50 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440179
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440211
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440225
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440237
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440293
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440307
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440417
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440461
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440475
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440503
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440573
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440605
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440621
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440635
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440649
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440663
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440677
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441571
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441585
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441599
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441617
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441631
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441685
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441699
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441713
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441727
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441741
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441799
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441813
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441827
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441841
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441855
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441871
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441895
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441909
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441931
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441942
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041441969
Principal investigator 1 ModernaTX, Inc. $1,216.38 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442003
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442013
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442025
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442039
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442053
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442079
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442117
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442131
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442146
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442171
Principal investigator 1 ModernaTX, Inc. $539.22 10/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041442185
Principal investigator 1 Novavax Inc $305.00 10/06/2023 Non-covered Recipient Entity
SANDHILL RESEARCH LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055263083
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041439583
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041439627
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041439641
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041439683
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041439699
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041439782
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041439855
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041439897
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041439911
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440025
Principal investigator 1 ModernaTX, Inc. $64.68 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440049
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440139
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440155
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440165
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440193
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440251
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440265
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440279
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440335
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440349
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440363
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440377
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440391
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440405
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440431
Principal investigator 1 ModernaTX, Inc. $64.68 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041440445
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440489
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440517
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440531
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440545
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440559
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440587
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440693
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440707
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440719
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440733
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440747
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440763
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440778
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440795
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440809
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440823
Principal investigator 1 GlaxoSmithKline, LLC. $1,956.22 10/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND-DELA
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1006257483
Principal investigator 1 Janssen Research & Development, LLC $12,050.00 10/04/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 986108231
Principal investigator 1 Averitas Pharma Inc. $75.00 10/03/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058764399
Principal investigator 1 Averitas Pharma Inc. $128.00 10/03/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058764401
Principal investigator 1 Averitas Pharma Inc. $128.00 10/03/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058764405
Principal investigator 1 Averitas Pharma Inc. $75.00 10/03/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058764409
Principal investigator 1 Boehringer Ingelheim International GmbH $19,150.00 10/02/2023 Non-covered Recipient Entity
Accel Research Sites Deland
MRD PoCP study in NFLD 12 wks No dispute reported 06/30/2026 1007646755
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/02/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041440321
Principal investigator 1 ModernaTX, Inc. $115.00 10/02/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041452229
Principal investigator 1 Janssen Research & Development, LLC $7,417.00 09/28/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108161
Principal investigator 1 Janssen Research & Development, LLC $210.00 09/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140209
Principal investigator 1 Bavarian Nordic A/S $500.00 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695115
Principal investigator 1 Bavarian Nordic A/S $3,280.50 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695121
Principal investigator 1 Bavarian Nordic A/S $1,093.50 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695127
Principal investigator 1 Bavarian Nordic A/S $2,187.00 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695133
Principal investigator 1 Bavarian Nordic A/S $4,374.00 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695139
Principal investigator 1 Bavarian Nordic A/S $455.00 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695145
Principal investigator 1 Bavarian Nordic A/S $682.50 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695151
Principal investigator 1 Bavarian Nordic A/S $910.00 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695159
Principal investigator 1 Bavarian Nordic A/S $817.50 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695165
Principal investigator 1 Bavarian Nordic A/S $3,280.50 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695219
Principal investigator 1 Bavarian Nordic A/S $2,187.00 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695225
Principal investigator 1 Bavarian Nordic A/S $1,093.50 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695231
Principal investigator 1 Bavarian Nordic A/S $1,093.50 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695237
Principal investigator 1 Bavarian Nordic A/S $1,093.50 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695243
Principal investigator 1 Bavarian Nordic A/S $682.50 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695251
Principal investigator 1 Bavarian Nordic A/S $455.00 09/27/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695255
Principal investigator 1 ModernaTX, Inc. $346,522.23 09/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450765
Principal investigator 1 Janssen Research & Development, LLC $5,710.00 09/26/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108181
Principal investigator 1 GlaxoSmithKline, LLC. $33,392.01 09/22/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1006257475
Principal investigator 1 Novo Nordisk AS $1,846.84 09/22/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007929835
Principal investigator 1 Novo Nordisk AS $859.10 09/22/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007929845
Principal investigator 1 Novo Nordisk AS $1,000.00 09/22/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 1008267731
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 09/20/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108179
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 09/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140207
Principal investigator 1 SANOFI PASTEUR INC. $500.00 09/15/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895663
Principal investigator 1 SANOFI PASTEUR INC. $650.00 09/15/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895699
Principal investigator 1 Chiesi USA, Inc. $2,524.00 09/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051607033
Principal investigator 1 Janssen Research & Development, LLC $6.00 09/14/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108155
Principal investigator 1 Janssen Research & Development, LLC $250.00 09/14/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108157
Principal investigator 1 Janssen Research & Development, LLC $110.00 09/14/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108159
Principal investigator 1 Novavax Inc $138.00 09/12/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260073
Principal investigator 1 Amgen Inc. $7,086.24 09/11/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES ACR
AMG 451 DDI/Atopic Dermatitis No dispute reported 06/30/2026 1029648211
Principal investigator 1 PFIZER INC. $915.00 09/09/2023 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046405961
Principal investigator 1 Janssen Research & Development, LLC $20.00 09/07/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108153
Principal investigator 1 ModernaTX, Inc. $4,745.93 09/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041439389
Principal investigator 1 ModernaTX, Inc. $20.25 09/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041439403
Principal investigator 1 Janssen Research & Development, LLC $6,273.00 09/06/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108151
Principal investigator 1 Janssen Research & Development, LLC $3,280.00 09/06/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108169
Principal investigator 1 Eli Lilly and Company $29,442.45 09/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PARALLEL-GROUP SINGLE-DOSE PHASE 1 OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1038151675
Principal investigator 1 Averitas Pharma Inc. $128.00 09/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058764395
Principal investigator 1 Averitas Pharma Inc. $150.00 09/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058764397
Principal investigator 1 GlaxoSmithKline, LLC. $2,317.27 09/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1006257469
Principal investigator 1 Janssen Pharmaceuticals, Inc $504.00 09/01/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093521
Principal investigator 1 SANOFI PASTEUR INC. $6,403.98 09/01/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895931
Principal investigator 1 Janssen Research & Development, LLC $15,131.00 08/31/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108167
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 08/29/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895797
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 08/29/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895807
Principal investigator 1 SANOFI PASTEUR INC. $6,403.98 08/29/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895917
Principal investigator 1 GlaxoSmithKline, LLC. $63,952.38 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1006257463
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438077
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438089
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438133
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438175
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438259
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438289
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438305
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438389
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438473
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438487
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438531
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438545
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438559
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438574
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438589
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438645
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438659
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438675
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438717
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438731
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438748
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439076
Principal investigator 1 ModernaTX, Inc. $99.00 08/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439253
Principal investigator 1 SANOFI PASTEUR INC. $100.00 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895625
Principal investigator 1 SANOFI PASTEUR INC. $320.76 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895638
Principal investigator 1 SANOFI PASTEUR INC. $1,187.34 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895709
Principal investigator 1 SANOFI PASTEUR INC. $1,187.34 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895723
Principal investigator 1 SANOFI PASTEUR INC. $1,187.34 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895735
Principal investigator 1 SANOFI PASTEUR INC. $1,187.34 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895763
Principal investigator 1 SANOFI PASTEUR INC. $2,245.32 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895785
Principal investigator 1 SANOFI PASTEUR INC. $2,374.68 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895819
Principal investigator 1 SANOFI PASTEUR INC. $3,288.12 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895845
Principal investigator 1 SANOFI PASTEUR INC. $3,562.02 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895893
Principal investigator 1 SANOFI PASTEUR INC. $3,562.02 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895905
Principal investigator 1 SANOFI PASTEUR INC. $9,906.47 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895979
Principal investigator 1 SANOFI PASTEUR INC. $11,873.40 08/28/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035896005
Principal investigator 1 SANOFI PASTEUR INC. $1,187.34 08/28/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915423
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438017
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438031
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438045
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438061
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438119
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438147
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438161
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438203
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438217
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438231
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438245
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438275
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438319
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438333
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438347
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438375
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438403
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438417
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438433
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438447
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438459
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438517
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438617
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438631
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438689
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438703
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438791
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438807
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438821
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438865
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438991
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439005
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439019
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439033
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439047
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439061
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439195
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439209
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439223
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439237
Principal investigator 1 ModernaTX, Inc. $99.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439347
Principal investigator 1 ModernaTX, Inc. $550.00 08/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448535
Principal investigator 1 PFIZER INC. $528,337.50 08/24/2023 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046402559
Principal investigator 1 Janssen Research & Development, LLC $10,758.00 08/23/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108177
Principal investigator 1 ModernaTX, Inc. $250.00 08/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438503
Principal investigator 1 ModernaTX, Inc. $250.00 08/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438779
Principal investigator 1 ModernaTX, Inc. $16,400.00 08/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041450939
Principal investigator 1 Averitas Pharma Inc. $128.00 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058764391
Principal investigator 1 Averitas Pharma Inc. $75.00 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058764393
Principal investigator 1 Janssen Research & Development, LLC $1,906.03 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140201
Principal investigator 1 Janssen Research & Development, LLC $100.00 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140203
Principal investigator 1 ModernaTX, Inc. $217.80 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437989
Principal investigator 1 ModernaTX, Inc. $297.00 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438003
Principal investigator 1 ModernaTX, Inc. $198.00 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438103
Principal investigator 1 ModernaTX, Inc. $217.80 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438189
Principal investigator 1 ModernaTX, Inc. $118.80 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438361
Principal investigator 1 ModernaTX, Inc. $64.68 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438762
Principal investigator 1 ModernaTX, Inc. $118.80 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438851
Principal investigator 1 ModernaTX, Inc. $297.00 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438963
Principal investigator 1 ModernaTX, Inc. $64.68 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439167
Principal investigator 1 ModernaTX, Inc. $297.00 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439181
Principal investigator 1 ModernaTX, Inc. $64.68 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439305
Principal investigator 1 ModernaTX, Inc. $198.00 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439317
Principal investigator 1 ModernaTX, Inc. $118.80 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439333
Principal investigator 1 Novavax Inc $1,800.00 08/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265019
Principal investigator 1 Novo Nordisk AS $1,870.83 08/18/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007822203
Principal investigator 1 ModernaTX, Inc. $2,149.27 08/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041438837
Principal investigator 1 Janssen Pharmaceuticals, Inc $50.00 08/16/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093525
Principal investigator 1 ModernaTX, Inc. $1,550.00 08/16/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041450815
Principal investigator 1 ModernaTX, Inc. $138.00 08/16/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041452261
Recipient Novavax Inc $166.57 08/16/2023 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055258319
Recipient Novavax Inc $182.03 08/16/2023 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055258443
Recipient Novavax Inc $190.97 08/16/2023 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055258635
Recipient Novavax Inc $353.70 08/16/2023 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055258637
Principal investigator 1 GlaxoSmithKline, LLC. $83,783.15 08/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1006257439
Principal investigator 1 Janssen Research & Development, LLC $4,183.00 08/11/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 986108171
Principal investigator 1 ModernaTX, Inc. $2,544.15 08/11/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041448721
Principal investigator 1 PFIZER INC. $150.00 08/11/2023 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046420119
Principal investigator 1 Novavax Inc $4,100.00 08/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055259111
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437011
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437025
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437041
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437055
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437069
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437083
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437097
Principal investigator 1 ModernaTX, Inc. $500.00 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041437111
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437125
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437139
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437153
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437167
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437181
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437195
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437207
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437221
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437235
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437249
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437263
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437277
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437291
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437305
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437319
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437333
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437347
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437363
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437379
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437393
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437405
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437419
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437429
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437443
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437460
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437472
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437487
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437497
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437511
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437525
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437537
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437551
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437563
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437573
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437583
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437597
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437611
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437629
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437647
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437663
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437677
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437691
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437705
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437719
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437735
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437749
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437763
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437777
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437791
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437805
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437819
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437837
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437849
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437863
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437877
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437893
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437905
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437919
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437933
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437945
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437959
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041437975
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438879
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438893
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438907
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438921
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438935
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438949
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041438977
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439091
Principal investigator 1 ModernaTX, Inc. $1,216.38 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439107
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439123
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439137
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439151
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439265
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439277
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439291
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439361
Principal investigator 1 ModernaTX, Inc. $539.22 08/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041439375
Principal investigator 1 SANOFI PASTEUR INC. $2,000.00 08/07/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895651
Principal investigator 1 SANOFI PASTEUR INC. $8,500.00 08/07/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035895747
Principal investigator 1 SANOFI PASTEUR INC. $500.00 08/07/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035896053
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 08/07/2023 Non-covered Recipient Entity
University Clinical Research,llc Dba Avail Clinical Research,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035896063
Principal investigator 1 GlaxoSmithKline, LLC. $12,008.90 08/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1006257451
Principal investigator 1 Janssen Research & Development, LLC $475.00 08/04/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108175
Principal investigator 1 ModernaTX, Inc. $1,000.00 08/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041448613
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041448629
Principal investigator 1 Janssen Research & Development, LLC $3,320.00 08/03/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140205
Principal investigator 1 Janssen Pharmaceuticals, Inc $31,843.00 08/02/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093523
Principal investigator 1 Janssen Research & Development, LLC $39,095.00 08/02/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108183
Principal investigator 1 ModernaTX, Inc. $2,000.00 08/02/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041448597
Principal investigator 1 ModernaTX, Inc. $42,462.29 08/02/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041450925
Principal investigator 1 Janssen Research & Development, LLC $960.00 07/31/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140193
Principal investigator 1 Janssen Research & Development, LLC $250.00 07/31/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140199
Principal investigator 1 Novo Nordisk AS $14.99 07/31/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472795
Principal investigator 1 Novo Nordisk AS $14.99 07/31/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472809
Principal investigator 1 Novo Nordisk AS $14.99 07/31/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472823
Principal investigator 1 Novo Nordisk AS $14.99 07/31/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472839
Principal investigator 1 Novo Nordisk AS $14.99 07/31/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472853
Principal investigator 1 Novo Nordisk AS $14.99 07/31/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472867
Principal investigator 1 ModernaTX, Inc. $3,000.00 07/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041448581
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 07/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140189
Principal investigator 1 Janssen Research & Development, LLC $450.00 07/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140191
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 07/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140197
Principal investigator 1 Boehringer Ingelheim International GmbH $3,535.13 07/26/2023 Non-covered Recipient Entity
Accel Research Sites Deland
MRD PoCP study in NFLD 12 wks No dispute reported 06/30/2026 1007644195
Principal investigator 1 Merck Sharp & Dohme LLC $6,700.00 07/26/2023 Non-covered Recipient Entity
Accel Research Sites-DeLand Clinical Research Unit
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 1042488569
Principal investigator 1 ModernaTX, Inc. $297.00 07/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041448707
Principal investigator 1 Novavax Inc $3,174.00 07/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259109
Principal investigator 1 Novo Nordisk AS $3,180.64 07/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007822197
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,965.00 07/21/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093519
Principal investigator 1 Janssen Research & Development, LLC $250.00 07/21/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108173
Principal investigator 1 Novo Nordisk AS $10.56 07/19/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007820313
Principal investigator 1 Novo Nordisk AS $10.56 07/19/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007820319
Principal investigator 1 Novo Nordisk AS $10.56 07/19/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007820325
Principal investigator 1 Novo Nordisk AS $10.56 07/19/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007820331
Principal investigator 1 Novo Nordisk AS $10.56 07/19/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007820337
Principal investigator 1 PFIZER INC. $1,485.00 07/13/2023 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046346667
Principal investigator 1 ModernaTX, Inc. $39,063.24 07/12/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041450799
Principal investigator 1 Janssen Research & Development, LLC $260.00 07/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140195
Principal investigator 1 ModernaTX, Inc. $79,737.32 07/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041450783
Principal investigator 1 Janssen Research & Development, LLC $120.00 07/04/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108163
Principal investigator 1 Janssen Research & Development, LLC $9,081.00 07/03/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108165
Principal investigator 1 PFIZER INC. $147.00 06/29/2023 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046529551
Principal investigator 1 Novavax Inc $2,565.00 06/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262067
Principal investigator 1 Eli Lilly and Company $416.40 06/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3857210 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 1038145303
Principal investigator 1 Eli Lilly and Company $1,976.55 06/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PARALLEL-GROUP SINGLE-DOSE PHASE 1 OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1038152869
Principal investigator 1 Janssen Research & Development, LLC $150.00 06/27/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108141
Principal investigator 1 Janssen Research & Development, LLC $834.00 06/26/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108149
Principal investigator 1 Bavarian Nordic A/S $500.00 06/25/2023 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH - DELAND LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988694827
Principal investigator 1 Novo Nordisk AS $1,484.14 06/23/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007822191
Principal investigator 1 Janssen Research & Development, LLC $2,592.00 06/21/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108139
Principal investigator 1 Novavax Inc $2,219.00 06/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055266033
Principal investigator 1 SANOFI PASTEUR INC. $500.00 06/19/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915305
Principal investigator 1 Janssen Research & Development, LLC $78.00 06/16/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108123
Principal investigator 1 Janssen Research & Development, LLC $222.00 06/16/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108125
Principal investigator 1 Janssen Research & Development, LLC $500.00 06/16/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108127
Principal investigator 1 PFIZER INC. $1,500.00 06/16/2023 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046502501
Principal investigator 1 American Regent $2,335.00 06/14/2023 Non-covered Recipient Entity
University Clinical Rsearch - Deland, Llc
Heart_FID No dispute reported 06/30/2026 989343105
Principal investigator 1 ModernaTX, Inc. $2,500.00 06/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041436591
Principal investigator 1 ModernaTX, Inc. $1,250.00 06/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041436603
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/14/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041436617
Principal investigator 1 Eli Lilly and Company $1,356.00 06/13/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES GEORGIA LLC
A MULTIPLE-DOSE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038064865
Principal investigator 1 Eli Lilly and Company $14,388.00 06/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 1038155935
Principal investigator 1 Novavax Inc $10,961.00 06/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055264007
Principal investigator 1 SANOFI PASTEUR INC. $2,717.40 06/13/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915347
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435171
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435185
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435197
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435211
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435223
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435237
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435253
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435269
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435283
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435297
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435309
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435325
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435339
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435351
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435363
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435377
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435393
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435405
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435419
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435435
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435449
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435467
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435481
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435495
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435511
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435523
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435537
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435551
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435565
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435579
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435593
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435606
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435621
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435635
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435651
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435665
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435679
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435693
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435707
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435721
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435735
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435749
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435763
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435777
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435791
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435805
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435819
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435833
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435847
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435861
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435875
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435889
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435903
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435917
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435931
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435945
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435961
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435975
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435991
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436005
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436019
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436631
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436645
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436659
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436675
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436689
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436703
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436715
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436729
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436744
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436757
Principal investigator 1 ModernaTX, Inc. $155.50 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436771
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436785
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436799
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436813
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436827
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436841
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436855
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436869
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436883
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436899
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436912
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436925
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436939
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436955
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436969
Principal investigator 1 ModernaTX, Inc. $539.22 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436983
Principal investigator 1 ModernaTX, Inc. $1,216.38 06/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436995
Principal investigator 1 Novavax Inc $3,333.00 06/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263095
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,450.00 06/07/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 991128061
Principal investigator 1 ModernaTX, Inc. $66.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433695
Principal investigator 1 ModernaTX, Inc. $66.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433707
Principal investigator 1 ModernaTX, Inc. $66.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433737
Principal investigator 1 ModernaTX, Inc. $66.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433751
Principal investigator 1 ModernaTX, Inc. $66.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433765
Principal investigator 1 ModernaTX, Inc. $66.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433779
Principal investigator 1 ModernaTX, Inc. $237.60 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433793
Principal investigator 1 ModernaTX, Inc. $118.80 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433807
Principal investigator 1 ModernaTX, Inc. $118.80 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433821
Principal investigator 1 ModernaTX, Inc. $118.80 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433835
Principal investigator 1 ModernaTX, Inc. $118.80 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433849
Principal investigator 1 ModernaTX, Inc. $217.80 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433863
Principal investigator 1 ModernaTX, Inc. $297.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433877
Principal investigator 1 ModernaTX, Inc. $297.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433891
Principal investigator 1 ModernaTX, Inc. $297.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433905
Principal investigator 1 ModernaTX, Inc. $594.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433921
Principal investigator 1 ModernaTX, Inc. $350.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433935
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433949
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433963
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433977
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433993
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434009
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434023
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434037
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434051
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434067
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434081
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434097
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434111
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434125
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434139
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434155
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434169
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434183
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434197
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434211
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434225
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434241
Principal investigator 1 ModernaTX, Inc. $198.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434253
Principal investigator 1 ModernaTX, Inc. $198.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434269
Principal investigator 1 ModernaTX, Inc. $198.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434283
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434295
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434307
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434323
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434337
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434351
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434365
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434379
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434393
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434407
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434423
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434437
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434453
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434467
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434483
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434497
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434511
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434525
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434537
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434553
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434567
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434581
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434595
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434609
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434623
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434638
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434655
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434669
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434683
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434697
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434711
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434725
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434739
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434753
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434769
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434783
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434801
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434815
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434829
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434843
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434857
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434871
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434885
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434901
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434915
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434929
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434945
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434957
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434971
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434985
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041434999
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435013
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435029
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435041
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435055
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435069
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435083
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435103
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435115
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435129
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435143
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041435157
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436033
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436047
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436059
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436073
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436087
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436101
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436117
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436133
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436145
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436159
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436175
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436191
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436205
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436219
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436231
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436245
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436257
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436271
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436285
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436299
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436313
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436327
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436345
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436359
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436373
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436389
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436401
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436419
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436433
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436449
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436461
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436475
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436489
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436505
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436519
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436533
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436547
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436561
Principal investigator 1 ModernaTX, Inc. $99.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041436575
Principal investigator 1 ModernaTX, Inc. $108,040.78 06/07/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041450891
Principal investigator 1 ModernaTX, Inc. $1,165.00 06/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041450749
Principal investigator 1 ModernaTX, Inc. $10,000.00 06/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041450909
Principal investigator 1 ModernaTX, Inc. $204.00 05/31/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1042041495
Principal investigator 1 Janssen Research & Development, LLC $11,676.00 05/30/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108131
Principal investigator 1 Novavax Inc $2,301.00 05/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055264005
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,450.00 05/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 991138405
Principal investigator 1 ModernaTX, Inc. $8,500.00 05/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1041450733
Principal investigator 1 Novo Nordisk AS $3,388.90 05/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007822179
Principal investigator 1 Novo Nordisk AS $500.00 05/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007822185
Principal investigator 1 SANOFI PASTEUR INC. $6,092.10 05/26/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915277
Principal investigator 1 SANOFI PASTEUR INC. $1,798.30 05/26/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915285
Principal investigator 1 SANOFI PASTEUR INC. $1,798.30 05/26/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915295
Principal investigator 1 UCB SA $12,400.00 05/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1059100891
Principal investigator 1 Eli Lilly and Company $1,431.78 05/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 1038151667
Principal investigator 1 Janssen Research & Development, LLC $834.00 05/24/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108147
Principal investigator 1 ModernaTX, Inc. $1,500.00 05/24/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041448657
Principal investigator 1 ModernaTX, Inc. $1,313.71 05/24/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041448673
Principal investigator 1 Novavax Inc $11,647.00 05/24/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055264009
Principal investigator 1 Averitas Pharma Inc. $925.00 05/19/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058764389
Principal investigator 1 ModernaTX, Inc. $6,441.60 05/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432331
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429441
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429455
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429469
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429487
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429501
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429513
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429527
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429540
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429553
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429569
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429583
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429597
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429611
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429625
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429641
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429655
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429669
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429683
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429697
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429709
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429725
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429740
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429751
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429761
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429773
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429785
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429797
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429807
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430859
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430873
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430887
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430901
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430915
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430929
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430943
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430957
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430969
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430987
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431001
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431015
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431029
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431043
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431057
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431071
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431085
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431101
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431117
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431133
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431145
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431161
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431175
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431189
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431203
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431217
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431231
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431245
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431259
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431275
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431289
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431302
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431317
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431331
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431347
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431361
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431375
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431389
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431403
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431419
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431433
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431447
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431461
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431475
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431489
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431505
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431519
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431533
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431547
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431561
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431577
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431591
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431606
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431618
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431631
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431643
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431663
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431677
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431691
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431705
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431719
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431733
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431747
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431761
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431775
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431789
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431803
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431817
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431831
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431845
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431861
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431875
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431891
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431905
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431917
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431935
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431949
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431967
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431981
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041431997
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432011
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432025
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432043
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432059
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432073
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432089
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432103
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432117
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432131
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432145
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432159
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432173
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432187
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432201
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432215
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432229
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432243
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432258
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432275
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432289
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432345
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432361
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432375
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432389
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432403
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432417
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432431
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432447
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432463
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432477
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432491
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432505
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432519
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432533
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432547
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432561
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432576
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432591
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432607
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432621
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432635
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432649
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432663
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432679
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432693
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432707
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432721
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432735
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432749
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432765
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432779
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432793
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432807
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432823
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432837
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432851
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432865
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432879
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432893
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432909
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432925
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432939
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432953
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432967
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432981
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041432995
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433009
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433025
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433039
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433053
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433067
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433079
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433095
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433109
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433123
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433137
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433153
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433167
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433181
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433195
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433209
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433223
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433237
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433251
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433265
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433277
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433291
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433307
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433321
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433335
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433349
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433365
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433379
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433393
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433409
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433423
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433437
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433451
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433467
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433481
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433495
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433509
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433523
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433539
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433553
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433567
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433581
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433593
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433609
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433627
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433641
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433655
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433669
Principal investigator 1 ModernaTX, Inc. $13.20 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041433683
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041448643
Principal investigator 1 Novavax Inc $5,634.00 05/16/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259107
Principal investigator 1 Novo Nordisk AS $23.13 05/16/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006862359
Principal investigator 1 Novo Nordisk AS $23.13 05/16/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006862371
Principal investigator 1 Novo Nordisk AS $23.13 05/16/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006862381
Principal investigator 1 Novo Nordisk AS $23.13 05/16/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472751
Principal investigator 1 Novo Nordisk AS $23.13 05/16/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472767
Principal investigator 1 Novo Nordisk AS $23.13 05/16/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472781
Principal investigator 1 Novo Nordisk AS $600.00 05/12/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 1008267717
Principal investigator 1 Chiesi USA, Inc. $500.00 05/11/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051595043
Principal investigator 1 Novavax Inc $7,875.00 05/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263093
Principal investigator 1 Janssen Research & Development, LLC $1,125.00 05/05/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108135
Principal investigator 1 Chiesi USA, Inc. $6,500.00 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051594329
Principal investigator 1 Chiesi USA, Inc. $3,807.00 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051594331
Principal investigator 1 Chiesi USA, Inc. $2,586.00 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051594333
Principal investigator 1 Chiesi USA, Inc. $1,106.00 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051594337
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428785
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428799
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428815
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428829
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428845
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428863
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428877
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428891
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428905
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428919
Principal investigator 1 ModernaTX, Inc. $155.50 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428933
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428949
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428963
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428979
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428993
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429009
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429023
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429037
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429053
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429069
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429081
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429095
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429111
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429125
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429137
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429149
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429197
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429211
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429225
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429239
Principal investigator 1 ModernaTX, Inc. $155.50 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429253
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429267
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429281
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429297
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429311
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429325
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429339
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429353
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429371
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429385
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429399
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429413
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429427
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429821
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429835
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429849
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429861
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429873
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429887
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429901
Principal investigator 1 ModernaTX, Inc. $155.50 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429913
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429927
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429943
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429957
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429971
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429987
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041429999
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430015
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430027
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430043
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430073
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430087
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430101
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430117
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430131
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430145
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430163
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430189
Principal investigator 1 ModernaTX, Inc. $155.50 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430203
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430219
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430235
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430249
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430263
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430283
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430297
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430311
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430327
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430341
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430355
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430369
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430383
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430399
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430415
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430429
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430442
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430455
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430470
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430487
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430501
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430515
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430529
Principal investigator 1 ModernaTX, Inc. $155.50 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430543
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430557
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430571
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430585
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430604
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430617
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430632
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430647
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430661
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430675
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430691
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430705
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430719
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430733
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430747
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430761
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430775
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430789
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430803
Principal investigator 1 ModernaTX, Inc. $1,216.38 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430817
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430831
Principal investigator 1 ModernaTX, Inc. $539.22 05/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041430845
Principal investigator 1 Novavax Inc $17,817.00 04/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055261069
Principal investigator 1 Novo Nordisk AS $3,113.85 04/26/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 1008267701
Principal investigator 1 Janssen Pharmaceuticals, Inc $896.00 04/21/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093517
Principal investigator 1 Janssen Research & Development, LLC $3,846.00 04/21/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108129
Principal investigator 1 Janssen Research & Development, LLC $5,173.00 04/21/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108133
Principal investigator 1 Janssen Research & Development, LLC $5,004.00 04/21/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108145
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 04/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 986140183
Principal investigator 1 ModernaTX, Inc. $10,000.00 04/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042041389
Principal investigator 1 Novavax Inc $885.00 04/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055259105
Principal investigator 1 Eli Lilly and Company $37,587.00 04/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1038149959
Principal investigator 1 Novavax Inc $354.00 04/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263089
Principal investigator 1 Novavax Inc $5,256.00 04/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265017
Principal investigator 1 Janssen Research & Development, LLC $250.00 04/17/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108143
Principal investigator 1 ModernaTX, Inc. $150.00 04/14/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES - ST. PETERSBURG- LARGO
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041511767
Principal investigator 1 Novavax Inc $4,779.00 04/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055261071
Principal investigator 1 Janssen Research & Development, LLC $400.00 04/12/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108137
Principal investigator 1 SANOFI PASTEUR INC. $128,584.77 04/10/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915337
Principal investigator 1 SANOFI PASTEUR INC. $6,642.65 04/07/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915325
Principal investigator 1 Eli Lilly and Company $102.20 04/05/2023 Non-covered Recipient Entity
ACHIEVE CLINICAL RESEARCH LLC
RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1038064885
Principal investigator 1 ModernaTX, Inc. $100.00 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448435
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041091
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041097
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041103
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041109
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041117
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041121
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041127
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041133
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041139
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041145
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041151
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041157
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041163
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041169
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041175
Principal investigator 1 ModernaTX, Inc. $155.50 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041181
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041187
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041193
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041199
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041205
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041211
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041217
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041223
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041229
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041235
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041241
Principal investigator 1 ModernaTX, Inc. $155.50 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041247
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041253
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041259
Principal investigator 1 ModernaTX, Inc. $155.50 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041267
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041273
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041279
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041285
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041291
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041297
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041303
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041309
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041315
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041321
Principal investigator 1 ModernaTX, Inc. $155.50 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041327
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041335
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041341
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041345
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041353
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041359
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041365
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041371
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041377
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041383
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041395
Principal investigator 1 ModernaTX, Inc. $1,285.35 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041403
Principal investigator 1 ModernaTX, Inc. $539.22 04/05/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042041409
Principal investigator 1 Novavax Inc $6,018.00 04/04/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260071
Principal investigator 1 ModernaTX, Inc. $66.00 03/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428045
Principal investigator 1 ModernaTX, Inc. $297.00 03/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428239
Principal investigator 1 ModernaTX, Inc. $2,317.23 03/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428295
Principal investigator 1 ModernaTX, Inc. $66.00 03/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428383
Principal investigator 1 ModernaTX, Inc. $66.00 03/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428399
Principal investigator 1 ModernaTX, Inc. $297.00 03/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428727
Principal investigator 1 ModernaTX, Inc. $1,500.00 03/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428743
Principal investigator 1 Averitas Pharma Inc. $256.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058764385
Principal investigator 1 Averitas Pharma Inc. $150.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058764387
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428005
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428019
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428033
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428059
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428077
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428091
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428105
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428117
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428125
Principal investigator 1 ModernaTX, Inc. $198.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428139
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428153
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428167
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428183
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428197
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428211
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428225
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428253
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428267
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428281
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428313
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428327
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428341
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428353
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428367
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428425
Principal investigator 1 ModernaTX, Inc. $66.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428439
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428453
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428469
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428511
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428525
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428539
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428555
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428571
Principal investigator 1 ModernaTX, Inc. $66.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428615
Principal investigator 1 ModernaTX, Inc. $500.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428629
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428643
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428655
Principal investigator 1 ModernaTX, Inc. $66.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428671
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428685
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428699
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428713
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428755
Principal investigator 1 ModernaTX, Inc. $99.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428769
Principal investigator 1 Novavax Inc $354.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260069
Principal investigator 1 Novavax Inc $1,133.00 03/29/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055263091
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007417595
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007417603
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007417613
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007417621
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007417629
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007417637
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007417645
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007417653
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007417661
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007544603
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007544617
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007544631
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007544645
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007544659
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007544675
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007544689
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007544701
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007544715
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007673715
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007673733
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007673745
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007673757
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007673771
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007673783
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007673795
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007797145
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007797153
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007797163
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007797171
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007797179
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007797187
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007797197
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007797205
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007797213
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007797221
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007820343
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007820351
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007927025
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008130465
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008130483
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008130497
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008130511
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008130525
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008130541
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008130555
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008130569
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008130585
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008130601
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008130617
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472881
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472891
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472903
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472911
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472925
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472939
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472955
Principal investigator 1 Novo Nordisk AS $18.25 03/29/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472973
Principal investigator 1 SANOFI PASTEUR INC. $71,325.28 03/29/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915265
Principal investigator 1 Janssen Pharmaceuticals, Inc $3,043.00 03/27/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093513
Principal investigator 1 Janssen Research & Development, LLC $3,194.34 03/24/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108083
Principal investigator 1 Novavax Inc $1,133.00 03/24/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265015
Principal investigator 1 Novavax Inc $5,841.00 03/24/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055266029
Principal investigator 1 Novo Nordisk AS $3,986.77 03/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008104415
Principal investigator 1 Novo Nordisk AS $11,236.65 03/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 1008267687
Principal investigator 1 Janssen Research & Development, LLC $5,331.00 03/23/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108089
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426573
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426587
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426601
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426615
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426629
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426643
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426657
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427193
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428411
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428483
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428497
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428585
Principal investigator 1 ModernaTX, Inc. $99.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041428599
Principal investigator 1 Janssen Pharmaceuticals, Inc $4,424.00 03/22/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093515
Principal investigator 1 Novavax Inc $6,195.00 03/21/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259103
Principal investigator 1 Novavax Inc $832.00 03/21/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055264001
Principal investigator 1 Janssen Research & Development, LLC $387.00 03/20/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108103
Principal investigator 1 Janssen Research & Development, LLC $3,475.00 03/20/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108109
Principal investigator 1 Janssen Research & Development, LLC $118.00 03/17/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108087
Principal investigator 1 Janssen Research & Development, LLC $31,652.00 03/17/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108105
Principal investigator 1 Janssen Research & Development, LLC $2,198.81 03/16/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108081
Principal investigator 1 Janssen Research & Development, LLC $25.00 03/16/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108085
Principal investigator 1 Janssen Research & Development, LLC $500.00 03/16/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108091
Principal investigator 1 Novavax Inc $3,540.00 03/16/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260067
Principal investigator 1 Novavax Inc $6,688.00 03/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055261073
Principal investigator 1 Novavax Inc $5,841.00 03/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055266031
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 03/14/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915155
Principal investigator 1 SANOFI PASTEUR INC. $500.00 03/14/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915165
Principal investigator 1 SANOFI PASTEUR INC. $750.00 03/14/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915177
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425059
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425071
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425085
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425099
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425115
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425133
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425147
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425161
Principal investigator 1 ModernaTX, Inc. $3,254.39 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425175
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425191
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425205
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425219
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425231
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425244
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425257
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425273
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425287
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425301
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425313
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425327
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425345
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425359
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425373
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425387
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425401
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425415
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425429
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425443
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425457
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425471
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425485
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425499
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425513
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425529
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425545
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425559
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425573
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425589
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425603
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425617
Principal investigator 1 ModernaTX, Inc. $600.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425631
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425645
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425659
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425673
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425687
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425701
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425715
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425729
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425745
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425757
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425772
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425787
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425801
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425817
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425833
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425845
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425859
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425875
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425889
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425903
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425917
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425931
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425945
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425959
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425973
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425987
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426001
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426015
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426029
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426044
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426061
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426075
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426089
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426105
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426119
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426133
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426147
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426161
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426175
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426189
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426203
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426217
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426231
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426245
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426259
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426273
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426289
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426303
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426317
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426331
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426345
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426361
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426375
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426389
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426403
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426417
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426431
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426445
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426461
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426471
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426484
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426499
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426515
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426531
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426545
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426559
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426671
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426687
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426699
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426713
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426727
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426741
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426759
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426775
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426789
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426801
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426817
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426831
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426845
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426859
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426873
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426887
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426905
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426921
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426935
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426949
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426963
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426977
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041426991
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427005
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427019
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427033
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427047
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427064
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427079
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427093
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427107
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427121
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427137
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427151
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427165
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427179
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427207
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427221
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427237
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427251
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427265
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427279
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427293
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427307
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427321
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427335
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427349
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427363
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427377
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427391
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427405
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427419
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427433
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427445
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427459
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427473
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427487
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427501
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427515
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427531
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427543
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427560
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427575
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427589
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427605
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427619
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427631
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427645
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427661
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427675
Principal investigator 1 ModernaTX, Inc. $539.22 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427693
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427707
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427721
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427737
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427749
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427763
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427775
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427791
Principal investigator 1 ModernaTX, Inc. $99.00 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427805
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427819
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427833
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427847
Principal investigator 1 ModernaTX, Inc. $1,216.38 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427861
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427873
Principal investigator 1 ModernaTX, Inc. $1,452.13 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427887
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427901
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427919
Principal investigator 1 ModernaTX, Inc. $1,925.52 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427935
Principal investigator 1 ModernaTX, Inc. $2,201.40 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427949
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427963
Principal investigator 1 ModernaTX, Inc. $155.50 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427977
Principal investigator 1 ModernaTX, Inc. $1,285.35 03/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041427989
Principal investigator 1 PFIZER INC. $8,534.16 03/11/2023 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046546487
Principal investigator 1 Janssen Research & Development, LLC $25.00 03/10/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108107
Principal investigator 1 Janssen Research & Development, LLC $25.00 03/10/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108121
Principal investigator 1 PFIZER INC. $94,605.36 03/09/2023 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046462545
Principal investigator 1 Novavax Inc $6,078.00 03/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260065
Principal investigator 1 Novavax Inc $3,186.00 03/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262065
Principal investigator 1 Janssen Research & Development, LLC $200.00 03/06/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108111
Principal investigator 1 Janssen Pharmaceuticals, Inc $50.00 03/03/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093505
Principal investigator 1 Novavax Inc $900.00 03/02/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265013
Principal investigator 1 ModernaTX, Inc. $50.00 03/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448421
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006713025
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006713043
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006713057
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006713073
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006713091
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007200415
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007200425
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007200435
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007200447
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007200457
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007204175
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007204185
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007204202
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007204217
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007204231
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007204245
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007530775
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007530789
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007530803
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007530817
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007530827
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007530843
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007530857
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007673809
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007772833
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007772839
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007772845
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007772851
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007772859
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007822155
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007822161
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007822166
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007822171
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008472987
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008473001
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008473013
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008473027
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008473043
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008473059
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008473073
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008473089
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008473101
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009274207
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009274225
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009274241
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009274259
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009274277
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009274293
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009274309
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009274331
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292475
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292491
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292507
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292523
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292541
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292557
Principal investigator 1 Novo Nordisk AS $14.25 03/01/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1009292575
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,235.37 02/28/2023 Non-covered Recipient Entity
University Clinical Research-deland Llc Dba Accel Research Sites
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 1027490339
Principal investigator 1 Novavax Inc $2,266.00 02/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055259097
Principal investigator 1 Novavax Inc $3,582.00 02/28/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259099
Principal investigator 1 Novo Nordisk AS $2.60 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006862321
Principal investigator 1 Novo Nordisk AS $2.60 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006862331
Principal investigator 1 Novo Nordisk AS $2.60 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006862340
Principal investigator 1 Novo Nordisk AS $2.60 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1006862349
Principal investigator 1 Novo Nordisk AS $26.86 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007543803
Principal investigator 1 Novo Nordisk AS $26.86 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007543815
Principal investigator 1 Novo Nordisk AS $26.86 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007543829
Principal investigator 1 Novo Nordisk AS $9.00 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007543843
Principal investigator 1 Novo Nordisk AS $20.52 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007543857
Principal investigator 1 Novo Nordisk AS $20.52 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007543871
Principal investigator 1 Novo Nordisk AS $20.52 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007543887
Principal investigator 1 Novo Nordisk AS $20.52 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007543899
Principal investigator 1 Novo Nordisk AS $20.52 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1007543913
Principal investigator 1 Novo Nordisk AS $20.52 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008093169
Principal investigator 1 Novo Nordisk AS $36.00 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008093183
Principal investigator 1 Novo Nordisk AS $9.80 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008093211
Principal investigator 1 Novo Nordisk AS $60.00 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008093225
Principal investigator 1 Novo Nordisk AS $2.60 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008093239
Principal investigator 1 Novo Nordisk AS $2.60 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008093255
Principal investigator 1 Novo Nordisk AS $2.60 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008093271
Principal investigator 1 Novo Nordisk AS $2.60 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008093286
Principal investigator 1 Novo Nordisk AS $2.60 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008093303
Principal investigator 1 Novo Nordisk AS $5.70 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008104429
Principal investigator 1 Novo Nordisk AS $26.86 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008104445
Principal investigator 1 Novo Nordisk AS $26.86 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008104459
Principal investigator 1 Novo Nordisk AS $26.86 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008104473
Principal investigator 1 Novo Nordisk AS $26.86 02/24/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008104491
Principal investigator 1 Janssen Pharmaceuticals, Inc $16,463.00 02/23/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093501
Principal investigator 1 Janssen Research & Development, LLC $1,341.00 02/22/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108119
Principal investigator 1 ModernaTX, Inc. $104.62 02/22/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450515
Principal investigator 1 Novavax Inc $14,740.00 02/22/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055261067
Principal investigator 1 Novavax Inc $10,443.00 02/22/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262061
Principal investigator 1 ModernaTX, Inc. $110.88 02/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423729
Principal investigator 1 ModernaTX, Inc. $66.00 02/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423743
Principal investigator 1 ModernaTX, Inc. $110.88 02/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423773
Principal investigator 1 ModernaTX, Inc. $110.88 02/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423803
Principal investigator 1 ModernaTX, Inc. $66.00 02/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423817
Principal investigator 1 ModernaTX, Inc. $66.00 02/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423859
Principal investigator 1 ModernaTX, Inc. $110.88 02/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423873
Principal investigator 1 ModernaTX, Inc. $110.88 02/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423887
Principal investigator 1 ModernaTX, Inc. $66.00 02/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423901
Principal investigator 1 Janssen Research & Development, LLC $19,672.00 02/17/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108095
Principal investigator 1 ModernaTX, Inc. $941.49 02/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450423
Principal investigator 1 ModernaTX, Inc. $8,473.39 02/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450437
Principal investigator 1 ModernaTX, Inc. $6,590.42 02/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450453
Principal investigator 1 ModernaTX, Inc. $9,414.88 02/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450469
Principal investigator 1 ModernaTX, Inc. $941.49 02/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450483
Principal investigator 1 ModernaTX, Inc. $2,057.13 02/17/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450499
Principal investigator 1 ModernaTX, Inc. $118.80 02/16/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423717
Principal investigator 1 ModernaTX, Inc. $118.80 02/16/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423759
Principal investigator 1 ModernaTX, Inc. $118.80 02/16/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423789
Principal investigator 1 ModernaTX, Inc. $118.80 02/16/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423831
Principal investigator 1 ModernaTX, Inc. $118.80 02/16/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423845
Principal investigator 1 Novavax Inc $50,875.00 02/16/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055259101
Principal investigator 1 Novavax Inc $5,664.00 02/16/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262063
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,916.00 02/15/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093503
Principal investigator 1 Janssen Research & Development, LLC $1,749.00 02/15/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108097
Principal investigator 1 ModernaTX, Inc. $941.49 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450157
Principal investigator 1 ModernaTX, Inc. $941.49 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450173
Principal investigator 1 ModernaTX, Inc. $941.49 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450183
Principal investigator 1 ModernaTX, Inc. $2,824.46 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450197
Principal investigator 1 ModernaTX, Inc. $941.49 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450213
Principal investigator 1 ModernaTX, Inc. $941.49 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450229
Principal investigator 1 ModernaTX, Inc. $2,824.46 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450245
Principal investigator 1 ModernaTX, Inc. $1,882.98 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450259
Principal investigator 1 ModernaTX, Inc. $2,824.46 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450275
Principal investigator 1 ModernaTX, Inc. $3,765.95 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450295
Principal investigator 1 ModernaTX, Inc. $1,882.98 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450313
Principal investigator 1 ModernaTX, Inc. $51,781.84 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450327
Principal investigator 1 ModernaTX, Inc. $32,952.08 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450343
Principal investigator 1 ModernaTX, Inc. $941.49 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450359
Principal investigator 1 ModernaTX, Inc. $18,829.76 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450373
Principal investigator 1 ModernaTX, Inc. $10,356.37 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450391
Principal investigator 1 ModernaTX, Inc. $13,180.83 02/15/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450409
Principal investigator 1 Novo Nordisk AS $29.50 02/14/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008093197
Principal investigator 1 Astellas Pharma Inc $1,700.00 02/13/2023 Non-covered Recipient Entity
ADVARRA INC DBA SCHULMAN ASSOCIATES
A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well No dispute reported 06/30/2026 1017348989
Principal investigator 1 Astellas Pharma Inc $1,097.00 02/13/2023 Non-covered Recipient Entity
ADVARRA INC DBA SCHULMAN ASSOCIATES
A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well No dispute reported 06/30/2026 1017348993
Principal investigator 1 Astellas Pharma Inc $273.00 02/13/2023 Non-covered Recipient Entity
ADVARRA INC DBA SCHULMAN ASSOCIATES
A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well No dispute reported 06/30/2026 1017349001
Principal investigator 1 ModernaTX, Inc. $4,707.44 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449932
Principal investigator 1 ModernaTX, Inc. $302.80 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449949
Principal investigator 1 ModernaTX, Inc. $605.60 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449965
Principal investigator 1 ModernaTX, Inc. $1,882.98 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449981
Principal investigator 1 ModernaTX, Inc. $2,824.46 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449997
Principal investigator 1 ModernaTX, Inc. $3,652.83 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450015
Principal investigator 1 ModernaTX, Inc. $3,652.83 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450031
Principal investigator 1 ModernaTX, Inc. $1,818.85 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450047
Principal investigator 1 ModernaTX, Inc. $908.40 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450063
Principal investigator 1 ModernaTX, Inc. $1,514.00 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450079
Principal investigator 1 ModernaTX, Inc. $1,514.00 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450097
Principal investigator 1 ModernaTX, Inc. $9,414.88 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450111
Principal investigator 1 ModernaTX, Inc. $302.80 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450127
Principal investigator 1 ModernaTX, Inc. $2,422.40 02/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041450141
Principal investigator 1 PFIZER INC. $96,355.50 02/10/2023 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046448639
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,250.00 02/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046565509
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $537.05 02/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046565545
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $750.00 02/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046565561
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,000.00 02/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046565725
Principal investigator 1 Eli Lilly and Company $26,550.00 02/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MULTIPLE-DOSE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038149967
Principal investigator 1 Novavax Inc $14,665.00 02/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055263997
Principal investigator 1 Novavax Inc $5,841.00 02/09/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263999
Principal investigator 1 SANOFI PASTEUR INC. $962.28 02/09/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915103
Principal investigator 1 SANOFI PASTEUR INC. $3,000.00 02/09/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915113
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 02/09/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915123
Principal investigator 1 SANOFI PASTEUR INC. $500.00 02/09/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915133
Principal investigator 1 Janssen Research & Development, LLC $566.00 02/08/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108099
Principal investigator 1 ModernaTX, Inc. $1,818.85 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449239
Principal investigator 1 ModernaTX, Inc. $2,725.20 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449251
Principal investigator 1 ModernaTX, Inc. $4,844.80 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449269
Principal investigator 1 ModernaTX, Inc. $9,132.07 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449281
Principal investigator 1 ModernaTX, Inc. $4,239.20 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449293
Principal investigator 1 ModernaTX, Inc. $16,005.30 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449309
Principal investigator 1 ModernaTX, Inc. $6,964.40 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449329
Principal investigator 1 ModernaTX, Inc. $17,888.27 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449343
Principal investigator 1 ModernaTX, Inc. $909.43 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449359
Principal investigator 1 ModernaTX, Inc. $605.60 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449375
Principal investigator 1 ModernaTX, Inc. $302.80 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449389
Principal investigator 1 ModernaTX, Inc. $45,191.42 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449407
Principal investigator 1 ModernaTX, Inc. $302.80 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449421
Principal investigator 1 ModernaTX, Inc. $62,138.21 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449437
Principal investigator 1 ModernaTX, Inc. $42,366.96 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449453
Principal investigator 1 ModernaTX, Inc. $908.40 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449469
Principal investigator 1 ModernaTX, Inc. $941.49 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449483
Principal investigator 1 ModernaTX, Inc. $3,652.83 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449501
Principal investigator 1 ModernaTX, Inc. $302.80 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449515
Principal investigator 1 ModernaTX, Inc. $605.60 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449531
Principal investigator 1 ModernaTX, Inc. $909.43 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449547
Principal investigator 1 ModernaTX, Inc. $302.80 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449565
Principal investigator 1 ModernaTX, Inc. $302.80 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449581
Principal investigator 1 ModernaTX, Inc. $1,826.41 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449597
Principal investigator 1 ModernaTX, Inc. $302.80 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449613
Principal investigator 1 ModernaTX, Inc. $908.40 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449629
Principal investigator 1 ModernaTX, Inc. $2,728.28 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449645
Principal investigator 1 ModernaTX, Inc. $605.60 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449664
Principal investigator 1 ModernaTX, Inc. $302.80 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449679
Principal investigator 1 ModernaTX, Inc. $302.80 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449693
Principal investigator 1 ModernaTX, Inc. $5,479.24 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449707
Principal investigator 1 ModernaTX, Inc. $909.43 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449725
Principal investigator 1 ModernaTX, Inc. $302.80 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449741
Principal investigator 1 ModernaTX, Inc. $1,211.20 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449755
Principal investigator 1 ModernaTX, Inc. $4,707.44 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449767
Principal investigator 1 ModernaTX, Inc. $1,826.41 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449783
Principal investigator 1 ModernaTX, Inc. $302.80 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449801
Principal investigator 1 ModernaTX, Inc. $1,882.98 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449819
Principal investigator 1 ModernaTX, Inc. $1,211.20 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449833
Principal investigator 1 ModernaTX, Inc. $1,211.20 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449853
Principal investigator 1 ModernaTX, Inc. $1,882.98 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449867
Principal investigator 1 ModernaTX, Inc. $9,132.07 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449885
Principal investigator 1 ModernaTX, Inc. $5,479.24 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449903
Principal investigator 1 ModernaTX, Inc. $9,414.88 02/08/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449917
Principal investigator 1 ModernaTX, Inc. $1,216.38 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420081
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420095
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420109
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420123
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420139
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420151
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420167
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420179
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420191
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420204
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420217
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420235
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420249
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420263
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420277
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420291
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420305
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420321
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420335
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420349
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420363
Principal investigator 1 ModernaTX, Inc. $1,216.38 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420377
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420391
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420405
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420417
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420431
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420445
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420459
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420473
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420487
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420503
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420517
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420531
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420545
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420563
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420579
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420599
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420613
Principal investigator 1 ModernaTX, Inc. $1,841.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420627
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420641
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420653
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420667
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420683
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420697
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420711
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420727
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420741
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420753
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420769
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420783
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420797
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420809
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420823
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420837
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420855
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420867
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420883
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420895
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420911
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420927
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420941
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420955
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420969
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420983
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420997
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421009
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421023
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421037
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421051
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421065
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421079
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421093
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421107
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421121
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421139
Principal investigator 1 ModernaTX, Inc. $63.36 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421151
Principal investigator 1 ModernaTX, Inc. $63.36 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421165
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421180
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421195
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421207
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421223
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421237
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421251
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421265
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421279
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421293
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421307
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421321
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421335
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421349
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421365
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421379
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421393
Principal investigator 1 ModernaTX, Inc. $1,216.38 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421407
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421421
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421435
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421451
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421465
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421479
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421493
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421507
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421521
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421537
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421553
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421567
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421579
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421593
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421605
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421621
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421635
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421649
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421663
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421679
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421693
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421707
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421723
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421737
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421749
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421763
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421779
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421795
Principal investigator 1 ModernaTX, Inc. $63.36 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421809
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421825
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421839
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421855
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421867
Principal investigator 1 ModernaTX, Inc. $1,216.38 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421883
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421897
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421911
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421923
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421939
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421953
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421971
Principal investigator 1 ModernaTX, Inc. $1,216.38 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421985
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041421997
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422011
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422025
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422039
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422053
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422065
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422077
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422090
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422103
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422113
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422125
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422137
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422150
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422161
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422173
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422187
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422201
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422211
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422223
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422241
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422255
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422269
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422283
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422297
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422311
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422325
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422339
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422353
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422367
Principal investigator 1 ModernaTX, Inc. $63.36 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422381
Principal investigator 1 ModernaTX, Inc. $1,216.38 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422397
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422409
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422423
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422437
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422453
Principal investigator 1 ModernaTX, Inc. $1,216.38 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422468
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422483
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422499
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422515
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422527
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422541
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422551
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422565
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422579
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422595
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422609
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422623
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422637
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422649
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422663
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422677
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422690
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422705
Principal investigator 1 ModernaTX, Inc. $1,216.38 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422719
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422735
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422747
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422761
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422779
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422793
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422807
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422821
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422835
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422849
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422863
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422877
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422891
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422905
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422919
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422933
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422947
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422963
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422977
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041422991
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423007
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423019
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423033
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423047
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423061
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423075
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423091
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423105
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423119
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423133
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423150
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423163
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423177
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423193
Principal investigator 1 ModernaTX, Inc. $1,216.38 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423207
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423221
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423237
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423251
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423265
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423281
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423293
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423305
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423319
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423335
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423351
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423365
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423377
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423393
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423407
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423421
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423435
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423449
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423461
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423475
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423489
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423501
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423515
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423529
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423543
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423559
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423571
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423585
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423599
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423613
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423629
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423643
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423657
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423669
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423685
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423701
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423915
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423927
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423941
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423957
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423971
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423985
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041423999
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424013
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424028
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424043
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424059
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424072
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424087
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424101
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424115
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424129
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424143
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424157
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424171
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424185
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424199
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424213
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424227
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424241
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424255
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424269
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424283
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424297
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424311
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424327
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424341
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424355
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424372
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424387
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424401
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424415
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424429
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424447
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424461
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424475
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424489
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424503
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424519
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424533
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424547
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424559
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424573
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424588
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424603
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424617
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424631
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424645
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424659
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424673
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424687
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424701
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424715
Principal investigator 1 ModernaTX, Inc. $1,000.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424729
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424743
Principal investigator 1 ModernaTX, Inc. $1,216.38 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424757
Principal investigator 1 ModernaTX, Inc. $99.00 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424769
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424783
Principal investigator 1 ModernaTX, Inc. $52.80 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424799
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424813
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424827
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424841
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424855
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424871
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424885
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424898
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424911
Principal investigator 1 ModernaTX, Inc. $1,925.52 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424927
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424942
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424955
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424971
Principal investigator 1 ModernaTX, Inc. $2,201.40 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424985
Principal investigator 1 ModernaTX, Inc. $1,452.13 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041424999
Principal investigator 1 ModernaTX, Inc. $539.22 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425013
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425029
Principal investigator 1 ModernaTX, Inc. $1,285.35 02/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041425045
Principal investigator 1 PFIZER INC. $54,980.50 02/03/2023 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046437971
Principal investigator 1 UCB SA $1,789.18 02/03/2023 Non-covered Recipient Entity
Accel Research Sites
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1059100879
Principal investigator 1 Emergent BioSolutions Inc. $1,475.48 02/02/2023 Non-covered Recipient Entity
University Clinical Research-Deland, LLC d/b/a Accel Research Sites
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 1042864559
Principal investigator 1 Novavax Inc $5,487.00 02/02/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263085
Principal investigator 1 Janssen Research & Development, LLC $500.00 02/01/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108117
Principal investigator 1 ModernaTX, Inc. $100.00 02/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448301
Principal investigator 1 ModernaTX, Inc. $100.00 02/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448313
Principal investigator 1 ModernaTX, Inc. $100.00 02/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448327
Principal investigator 1 ModernaTX, Inc. $100.00 02/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448343
Principal investigator 1 ModernaTX, Inc. $100.00 02/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448355
Principal investigator 1 ModernaTX, Inc. $100.00 02/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448373
Principal investigator 1 ModernaTX, Inc. $100.00 02/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448389
Principal investigator 1 ModernaTX, Inc. $100.00 02/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448405
Principal investigator 1 ModernaTX, Inc. $875.95 02/01/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449225
Principal investigator 1 Eli Lilly and Company $1,860.58 01/31/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1038150659
Principal investigator 1 Janssen Research & Development, LLC $118.00 01/31/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986108093
Principal investigator 1 Novo Nordisk AS $8,000.00 01/31/2023 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1008104401
Principal investigator 1 SANOFI PASTEUR INC. $750.00 01/31/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915187
Principal investigator 1 SANOFI PASTEUR INC. $1,250.00 01/31/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915197
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 01/31/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915209
Principal investigator 1 Janssen Research & Development, LLC $513.50 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140185
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418043
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418057
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418071
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418085
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418099
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418113
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418127
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418141
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418155
Principal investigator 1 ModernaTX, Inc. $198.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418169
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418183
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418197
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418211
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418225
Principal investigator 1 ModernaTX, Inc. $1,500.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418239
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418253
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418267
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418281
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418295
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418309
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418323
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418339
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418355
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418369
Principal investigator 1 ModernaTX, Inc. $198.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418385
Principal investigator 1 ModernaTX, Inc. $100.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418399
Principal investigator 1 ModernaTX, Inc. $100.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418411
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418427
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418441
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418455
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418469
Principal investigator 1 ModernaTX, Inc. $100.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418483
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418497
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418511
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418525
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418542
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418557
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418569
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418583
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418599
Principal investigator 1 ModernaTX, Inc. $2,317.23 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418613
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418627
Principal investigator 1 ModernaTX, Inc. $198.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418643
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418657
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041418671
Principal investigator 1 ModernaTX, Inc. $2,317.23 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419471
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419485
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419499
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419513
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419527
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419540
Principal investigator 1 ModernaTX, Inc. $500.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419555
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419569
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419581
Principal investigator 1 ModernaTX, Inc. $198.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419595
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419607
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419623
Principal investigator 1 ModernaTX, Inc. $100.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419637
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419651
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419665
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419679
Principal investigator 1 ModernaTX, Inc. $1,245.61 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419695
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419711
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419727
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419741
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419755
Principal investigator 1 ModernaTX, Inc. $100.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419769
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419783
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419795
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419811
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419825
Principal investigator 1 ModernaTX, Inc. $7,500.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419839
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419851
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419865
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419879
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419893
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419908
Principal investigator 1 ModernaTX, Inc. $750.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419921
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419935
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419953
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419967
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419981
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041419993
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420015
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420027
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420041
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420053
Principal investigator 1 ModernaTX, Inc. $99.00 01/30/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041420067
Principal investigator 1 Janssen Research & Development, LLC $1,960.00 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 986140179
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 986140181
Principal investigator 1 ModernaTX, Inc. $141.07 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448135
Principal investigator 1 ModernaTX, Inc. $26,780.75 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448153
Principal investigator 1 ModernaTX, Inc. $337.50 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448169
Principal investigator 1 ModernaTX, Inc. $26,865.00 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448185
Principal investigator 1 ModernaTX, Inc. $27,000.00 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448203
Principal investigator 1 ModernaTX, Inc. $35,884.50 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448219
Principal investigator 1 ModernaTX, Inc. $40,500.00 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448233
Principal investigator 1 ModernaTX, Inc. $58,155.00 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448251
Principal investigator 1 ModernaTX, Inc. $86,400.00 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448265
Principal investigator 1 ModernaTX, Inc. $47,694.70 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448283
Principal investigator 1 ModernaTX, Inc. $40,297.50 01/27/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041449211
Principal investigator 1 SANOFI PASTEUR INC. $135,086.76 01/27/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915255
Principal investigator 1 Eli Lilly and Company $1,692.68 01/26/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MULTIPLE-DOSE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038152017
Principal investigator 1 SANOFI PASTEUR INC. $7,500.00 01/26/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915083
Principal investigator 1 SANOFI PASTEUR INC. $3,500.00 01/26/2023 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035915093
Principal investigator 1 Janssen Pharmaceuticals, Inc $41,741.00 01/25/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093507
Principal investigator 1 Janssen Research & Development, LLC $139.00 01/25/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108113
Principal investigator 1 ModernaTX, Inc. $13,122.00 01/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448119
Principal investigator 1 Novavax Inc $7,135.00 01/25/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260063
Principal investigator 1 Averitas Pharma Inc. $256.00 01/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058764383
Principal investigator 1 Janssen Pharmaceuticals, Inc $322.00 01/20/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093509
Principal investigator 1 Novavax Inc $14,520.00 01/20/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263087
Principal investigator 1 Janssen Research & Development, LLC $11,062.50 01/19/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986140187
Principal investigator 1 PFIZER INC. $8,000.00 01/19/2023 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046537687
Principal investigator 1 Janssen Research & Development, LLC $358.00 01/18/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986108101
Principal investigator 1 ModernaTX, Inc. $12,245.71 01/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448075
Principal investigator 1 ModernaTX, Inc. $1,309.77 01/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448089
Principal investigator 1 ModernaTX, Inc. $500.00 01/18/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448105
Principal investigator 1 Eli Lilly and Company $1,273.46 01/13/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 1038140123
Principal investigator 1 Janssen Pharmaceuticals, Inc $300.00 01/11/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093511
Principal investigator 1 ModernaTX, Inc. $104,215.95 01/11/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041448059
Principal investigator 1 Novavax Inc $5,221.00 01/10/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260061
Principal investigator 1 Eli Lilly and Company $44,207.25 01/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 1038151681
Principal investigator 1 Novavax Inc $31,518.00 01/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263995
Principal investigator 1 Novavax Inc $2,325.00 01/06/2023 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055266027
Principal investigator 1 Janssen Research & Development, LLC $25.00 01/04/2023 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986108115
Principal investigator 1 Eli Lilly and Company $103.53 01/03/2023 Non-covered Recipient Entity
MERIDIEN RESEARCH
RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1038110877